[Expression of miR-342-3p in rheumatoid arthritis patients and its effect on synovial fibroblast inflammation and migration]

Nan Fang Yi Ke Da Xue Xue Bao. 2022 Nov 20;42(11):1712-1719. doi: 10.12122/j.issn.1673-4254.2022.11.16.
[Article in Chinese]

Abstract

Objective: To investigate the expression level of miR-342-3p in peripheral blood mononuclear cells (PBMCs) of patients with rheumatoid arthritis (RA) and its effect on inflammatory response and migration of synovial fibroblasts in RA (RA-FLS).

Methods: PBMCs were collected from 30 healthy individuals and 50 RA patients for detecting the expression of miR-342-3p, and its correlation with the clinical indicators RF, ESR, anti-CCP, hs-CRP, C3, DAS-28, SAS, and SDS was analyzed. In RA-FLS cultures, the effect of transfection of miR-342-3p mimics and inhibitor on TNF-α-induced inflammatory response of the cells was evaluated by detecting the expressions of IL-1β, IL-6, IL-10, and TNF-α using ELISA. CCK8 assay and Transwell assay were used for detecting the changes in cell viability and migration ability of the synovial cells.

Results: In RA patients, the expression level of miR-342-3p was significantly lowered in the PBMCs (P < 0.05) with an area under the ROC curve of 97.53% and showed inverse correlations with RF (r=-0.321), ESR(r=-0.284), anti-CCP (r=-0.355), hs-CRP (r=-0.320), C3 (r=-0.294), DAS-28 (r=-0.395), SAS (r=-0.366), and SDS (r=-0.397) (all P < 0.05); a low expression of miR-342-3p was strongly associated with elevated levels of anti-CCP, DAS-28, SDS, and SAS (all with a rule support greater than 85%, confidence greater than 88%, and lift greater than 1). In cultured RA-FLS, TNF-α stimulation significantly increased the cell viability (P < 0.05), upregulated the expressions of IL-1β, IL-6, and TNF-α, and lowered the expression of IL-10 (P < 0.05). These changes were significantly suppressed by transfection of the cells with miR-342-3p mimics (P < 0.05) but enhanced by transfection with miR-342-3p inhibitor (P < 0.05).

Conclusion: The expression of miR-342-3p is decreased in the PBMCs of RA patients. A lowered expression of miR-342-3p contributes to the pathogenesis of RA by promoting inflammatory responses and migration of RA-FLS.

目的: 探究类风湿关节炎(RA)患者miR-342-3p的表达,及其对类风湿性关节炎滑膜成纤维细胞细胞(RA-FLS)炎症和迁移的影响。

方法: 收集正常人30例、RA患者50例外周血单个核细胞(PBMCs),检测PBMCs中miR-342-3p的表达,并研究其与临床指标RF、ESR、anti-CCP、hs-CRP、C3、DAS-28、SAS、SDS的相关性。建立RA-FLS细胞系,20 ng/mL TNF-α刺激细胞,构建mimics-miR-342-3p和inhibitor-miR-342-3p及空转组,转染至RA-FLS中;实验分为6组:RA-FLS组,TNF-α+RA-FLS组,mimics-NC组,mimics-miR-342-3p组,inhibitor-NC组和inhibitor-miR-342-3p组;采用定量实时聚合酶链反应(RT-qPCR)检测miR-342-3p的表达;酶联免疫吸附法(ELISA)检测白介素-1β(IL-1β)、白介素-6(IL-6)、白介素-10(IL-10)、肿瘤坏死因子-α(TNF-α)的表达。CCK8检测细胞活力。Transwell小室检测滑膜细胞的迁移。

结果: 与正常组相比,RA患者miR-342-3p表达显著降低(P<0.05),ROC曲线结果显示AUC 97.53%。miR-342-3p与RF(r=-0.321)、ESR(r=-0.284)、anti-CCP(r=-0.355)、hs-CRP(r=-0.320)、C3(r=-0.294)、DAS-28(r=-0.395)、SAS(r=-0.366)、SDS(r=-0.397)呈显著负相关(P<0.05)。miR-342-3p与anti-CCP、DAS-28、SDS、SAS的升高有较强的关联,规则支持均大于85%、置信度均大于88%和提升均大于1;与RA-FLS组相比,TNF-α刺激后细胞活力显著升高(P<0.05),IL-1β、IL-6、TNF-α表达显著升高,IL-10的表达显著降低(P<0.05);与mimics-NC组相比,mimics-miR-342-3p组细胞活力显著降低(P<0.05);与inhibitor-NC组相比,inhibitor-miR-342-3p组细胞活力显著升高(P<0.05);与mimics-NC组相比,mimics-miR-342-3p组IL-1β、IL-6、TNF-α表达显著降低,IL-10的表达显著升高(P<0.05);与inhibitor-NC组相比,inhibitor-miR-342-3p组IL-1β、IL-6、TNF-α表达显著升高,IL-10的表达显著降低(P<0.05)。

结论: miR-342-3p在RA患者中表达降低,通过促进RA-FLS炎症和迁移,参与RA的发病机制。

Keywords: inflammation; miR-342-3p; migration; rheumatoid arthritis.

Publication types

  • English Abstract

MeSH terms

  • Anti-Citrullinated Protein Antibodies
  • Arthritis, Rheumatoid*
  • C-Reactive Protein
  • Fibroblasts
  • Humans
  • Inflammation
  • Interleukin-10
  • Interleukin-6
  • Leukocytes, Mononuclear
  • MicroRNAs* / genetics
  • Tumor Necrosis Factor-alpha

Substances

  • Anti-Citrullinated Protein Antibodies
  • Interleukin-10
  • Tumor Necrosis Factor-alpha
  • C-Reactive Protein
  • Interleukin-6
  • MicroRNAs
  • MIRN342 microRNA, human

Grants and funding

科技部国家重点研发计划中医药现代化研究(2018YFC1705204);国家自然科学基金(82074373,81973655);安徽省高校协同创新项目(GXXT-2020-025);安徽现代中医内科应用基础与开发研究省级实验室项目(2016080503B041);安徽省第12批“115”创新团队(皖人才办[2019]1号);安徽省重大疑难病中西医协同攻关项目(皖中医药发展秘[2021]70号)